DrugDashboards

Sensorcaine

BUPIVACAINE HYDROCHLORIDE and EPINEPHRINE BITARTRATE · BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL · Injection, Solution · Infiltration; Perineural · Fresenius Kabi USA, LLC

NDC 63323-0461-57 · 25 VIAL, MULTI-DOSE in 1 TRAY / 50 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “delay in shipping of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Part D plans paid (avg)$0.1949per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$197.55per package of 25X50MLFresenius Kabi, LLC · May 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$485.00
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$12,608
1,108 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $16.83 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA070967
TE code
AP
Approval date
Oct 13, 1987
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)Feb 20, 2018
    Delay in shipping of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
  • In shortage now — Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · TerminatedNov 22, 2022
    Fresenius Kabi USA, LLC — Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
  • Class II · TerminatedNov 22, 2022
    Fresenius Kabi USA, LLC — Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
  • Class II · TerminatedNov 22, 2022
    Fresenius Kabi USA, LLC — Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
  • Class II · TerminatedApr 25, 2016
    Fresenius Kabi USA, LLC — Presence of Particulate Matter: Glass particulate found in sterile injectable product

Manufacturers of BUPIVACAINE HYDROCHLORIDE and EPINEPHRINE BITARTRATE (Injection, Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mLJul 15, 2026Sep 3, 2026
Septodont, Inc.BUPIVACAINE HYDROCHLORIDE ANHYDROUS 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mLJul 15, 2026Sep 3, 2026
Sportpharm LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mLSep 3, 2026Sep 3, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mLJul 15, 2026Aug 31, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sensorcaine — NDC 63323-0461-57," retrieved September 3, 2026, https://drugdashboards.com/drug/63323046157.

Free to cite with attribution — see how the data is put together.